AMLODIPINE/VALSARTAN NOVARTIS 5/320 amlodipine 5 mg/valsartan 320 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis 5/320 amlodipine 5 mg/valsartan 320 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hypromellose; purified talc; iron oxide red; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN NOVARTIS 10/160 amlodipine 10 mg/valsartan 160 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis 10/160 amlodipine 10 mg/valsartan 160 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN NOVARTIS 5/160 amlodipine 5 mg/valsartan 160 mg film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis 5/160 amlodipine 5 mg/valsartan 160 mg film-coated tablets blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Fluorescein Novartis Australia - English - Department of Health (Therapeutic Goods Administration)

fluorescein novartis

novartis pharmaceuticals australia pty ltd - fluorescein sodium -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p Australia - English - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

Prexige New Zealand - English - Medsafe (Medicines Safety Authority)

prexige

novartis new zealand ltd - lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 100 mg - active: lumiracoxib 100mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry   opadry white 00f18296 povidone titanium dioxide

Prexige New Zealand - English - Medsafe (Medicines Safety Authority)

prexige

novartis new zealand ltd - lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 200 mg - active: lumiracoxib 200mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry black 00f17713 opadry red 00f15613 opadry white 00f18296 povidone titanium dioxide

Prexige New Zealand - English - Medsafe (Medicines Safety Authority)

prexige

novartis new zealand ltd - lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) - film coated tablet - 400 mg - active: lumiracoxib 400mg (release testing to occur at novartis ag, lichstrasse, basel.) excipient: croscarmellose sodium 00f17713 basic coating premix black magnesium stearate microcrystalline cellulose opadry opadry white 00f18296 povidone